<DOC>
	<DOCNO>NCT02478788</DOCNO>
	<brief_summary>The main purpose study see affect study medication call mixed amphetamine salts-extended release ( MAS-XR ) brain function take brain picture . The researcher also want see MAS-XR make child less likely develop problem like act ( i.e . period irritability , agitation , aggression ) . MAS-XR approve United States Food Drug Administration ( FDA ) treat attention deficit hyperactivity disorder ( ADHD ) adult , child adolescent .</brief_summary>
	<brief_title>Neuroimaging Study Risk Factors Adolescent Bipolar Disorder</brief_title>
	<detailed_description>A 12-week prospective study two group adolescent ( age 13-17 year ) attention deficit/hyperactivity disorder ( ADHD ) ; 1 ) ADHD adolescent parent bipolar disorder ( `` high-risk '' ) 2 ) ADHD adolescent without first second degree-relatives bipolar disorder ( `` low-risk '' ) . Patients evaluate use diagnostic interview symptom rating , receive neuroimaging scan ( fMRI , DTI , 1H MRS ) , assign treatment . Low-risk ADHD adolescent ( n=60 ) receive treatment open-label mixed amphetamine salts-extended release ( MAS-XR ) , approve United States Food Drug Administration ( USFDA ) treatment ADHD commonly prescribe psychostimulant medication adolescent ADHD . High-risk ADHD adolescent randomize double-blind treatment MAS-XR ( n=60 ) placebo ( n=60 ) . Following initiation treatment , ADHD adolescents regularly schedule visit symptom tolerability rating perform . Healthy subject ( n=60 ) recruit community receive medication undergo magnetic resonance imaging ( MRI ) scan intervals ass normal variability image parameter time point well adjust interpret comparison within patient ( i.e. , whether patient value change toward away healthy adolescent ) . Neuroimaging ( fMRI , DTI,1H MRS ) evaluation perform baseline Week 12 ( termination ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<criteria>Ages 1317 year old Tanner stage IIIV If female , pregnant Fluent English No contraindication MRI scan ( e.g. , brace claustrophobia ) An IQ &gt; 80 No unstable major medical neurological illness No lifetime DSM5 substance use disorder Lives &lt; 100 mile University Cincinnati Provision write informed consent/assent At least one biological parent bipolar I disorder ( 'highrisk ' ) No first seconddegree relative mood psychotic disorder ( 'lowrisk ' healthy control ) . No lifetime DSM5 Axis I disorder ( healthy control ) . No medication CNS effect within 5 halflives baseline MR scan ( healthy control ) . Inclusion criterion 'highrisk ' 'lowrisk ' ADHD subject : Meets DSM5 criterion ADHD , inattentive , hyperactive/impulsive , combine type Less 3 month cumulative lifetime exposure psychostimulants ADHD medication none year prior baseline No lifetime exposure mood stabilizer antipsychotic medication No concomitant use psychotropic medication study medication study participation No history intolerance , hypersensitivity , nonresponse MASXR No comorbid mood , anxiety , conduct , eat psychotic disorder , Tourette 's disorder , chronic tic disorder , pervasive developmental disorder . No clinically significant ECG blood pressure abnormalities No family history sudden death ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>ADHD</keyword>
</DOC>